Knight Therapeutics Inc T.GUD

Annual Report is now available ...

[MrMugsy]

Rest of world strategy Knight has successfully completed the acquisition of 99.9% of Grupo Biotoscana and made significant headway in the integration of ten countries in Latin America and 700 employees. With this acquisition, Knight has established a strong panAmerican (ex-US) infrastructure which enables Knight to become a one stop shop and a partner of choice for pharmaceutical companies looking to commercialize their innovative products.


Financial Results • Revenues were $199,519, an increase of $152,058 or 320% over prior year. • Gross margin generated of $81,690 or 41% compared to $26,918 or 57% in prior year. • Adjusted EBITDA1 was $16,837 compared to $2,827 in prior year. • Interest income generated of $14,322 a decrease of $9,220 or 39% over prior year. • Gain from strategic fund investments of $46,733, of which $16,644 was realized. • Adjusted earnings1 of $28,713, an increase of $2,714 or 10% over prior year. • Net income was $31,760 compared to net income of $18,033 in prior year.

Corporate Development • Promoted Arvind Utchanah from VP Finance to CFO. • Accepted the resignation of Nancy Harrison, Sylvie Tendler and Kevin Cameron and appointed Janice Murray and Nicols Sujoy on the Board of Directors. • Disposed the shares of Medison for a cash consideration of $77,000 and recorded a gain of $2,948. • Purchased 5,748,716 common shares and at an average price of $6.40 per share through a NCIB. • Completed the tender offer process for an aggregate purchase price of $170,855 and achieved 99.9% ownership of GBT. • Filed a short form base shelf prospectus in December 2020 which enables Knight to offer for sale and issue up to $360,000 in common shares, subscription receipts and debt securities from time to time during the 25-month period during which the shelf prospectus remains valid.

-------------------

Foundation in place.
Profitable.
Washed their hands of Meir/Cameron (and that soap opera)
Now they need to improve the efficiencies of GBT and the business as a whole - lots of low hanging fruit (if you will).

[gudisgood]

After reading the annual report and listening to the conference call, I feel good about owning GUD stock. When looking at the numbers, no matter how slow the last year felt, Knight's progress is impressive. The management sounded confident and in good spirits. They now have a good idea of what GBT is like and I'm willing to bet they've found plenty of inefficiencies within the company

[Chianchin]

Progress..........????? Share price for $10.70 to $5.50?  Six Years latter...

[gudisgood]

I mean progress if you look at the underlying business. In fact, the business set-up is completely different now when compared to, say, two years ago. Still lots of cash, but the company just produced $30M of net income last year, has a strong platform for product acquisitions, is in the approval or launch phase for many products, and the integration is still a year away from being completed. In

[Chianchin]

Good luck, no one has had any so far except for short sellers.